| pubmed-article:1100915 | pubmed:abstractText | CCNU is a useful drug in treating advanced ovarian carcinoma. Of patients with advanced ovarian carcinoma 37% responded favorably to CCNU. Thrombocytopenia was the primary toxic reaction. Clinical trials are in progress to compare the relative effectiveness, the degree of cross-resistance, and the difference in toxicity between CCNU and alkylating agents. | lld:pubmed |
